

Invitation to third quarter financial report and business update

Mendus AB ("Mendus" publ; IMMU.ST), will publish its interim report for the third quarter 2024 on November 8 at 08.00 CET. The company will host a live presentation and business update on the same day at 14.00 CET. The presentation will be held in English and includes a Q&A session.

Date and time: November 8 at 14.00 CET

If you wish to participate via webcast please use the link below.

<https://ir.financialhearings.com/mendus-q3-report-2024/register>

If you wish to participate and ask questions via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference.

<https://conference.financialhearings.com/teleconference/?id=50049745>

For more information, please contact:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>